Who
John W. Kozarich
Director
Company insider
Files Form 4 as: Director, Ligand Pharmaceuticals; Director, Intec Pharma; Director, Travere Therapeutics; Director, Qlt Inc/bc; Director, Corium International.
In numbers
- Trades disclosed
- 258
- Buys
- 15
- Sells
- 30
- Bought
- $395K
- Sold
- $7.8M
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 4 Jan 2006
- Last trade
- 5 Jun 2026
- Last filed
- 9 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,938 at $0.00 | filing |
| 5 Jun 2026filed 9 Jun 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —836 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,575 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,575 at $0.00 | filing |
| 13 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $109K1,575 at $69.51 | filing |
| 13 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $109K1,575 at $69.51 | filing |
| 13 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $352K1,575 at $223.50 | filing |
| 13 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $352K1,575 at $223.50 | filing |
| 12 May 2026filed 14 May 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —459 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | LGND Ligand Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —459 at $0.00 | filing |
| 12 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $32K459 at $69.51 | filing |
| 12 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $103K459 at $224.00 | filing |
| 12 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $32K459 at $69.51 | filing |
| 12 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $103K459 at $224.00 | filing |
| 1 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $18K80 at $227.37 | filing |
| 1 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $2301 at $229.87 | filing |
| 1 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $38K165 at $231.87 | filing |
| 1 May 2026filed 14 May 2026 | LGND Ligand PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $24K105 at $232.57 | filing |
News
No headline names them, or the companies they trade most, lately.